Netakimab

Phase 3Monoclonal antibody

SSPH-BIOCAD (HK) Limited

Netakimab is one of 57 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

COVID-19Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Netakimab

SSPH-BIOCAD (HK) Limited

Phase 3

1 2

SARS-COV-2 VACCINE

Moderna

Preclinical

2 3

Blood Taken

HHospices Civils de Lyon

Preclinical

1 4

Other Tkis

Bayer

Preclinical

1 5

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

1 6

Immunosuppressive

Chiesi Farmaceutici S.p.A.

Preclinical

1 7

Stools

VVersailles Hospital

Preclinical

1 8

Serology Test

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Huashi Baidu Granule

XXiyuan Hospital of China Academy of Chinese Medical Sciences

Preclinical

1 10

Coronavac COVID-19 Vaccine

HHospital Moinhos de Vento

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Psoriasis

NCT06640517

Clinical

Trials by Indication[1]

COVID-191 trial

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed·PPirogov Russian National Research Medical University··NCT05302947·154 enrolled

Ankylosing Spondylitis1 trial

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

Completed·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07277179·113 enrolled

Psoriasis1 trial

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Active, not recruiting·BBiocad·Phase 3·NCT06640517·140 enrolled

Plaque Psoriasis1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Moderate to Severe Plaque Psoriasis

Completed·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07008547·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Netakimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netakimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netakimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SPH-BIOCAD (HK) Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SSPH-BIOCAD (HK) Limited

Netakimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

COVID-191 trial

Ankylosing Spondylitis1 trial

Psoriasis1 trial

Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News